630067-21-9

Basic information

• Product Name: 4,7-dichloroquinoline-3-carboxylic acid
• Synonyms: 4,7-dichloroquinoline-3-carboxylic acid;4,7-dichloro-3-Quinolinecarboxylic acid
• CAS NO: 630067-21-9
• Molecular Formula: C10H5Cl2NO2
• Molecular Weight: 242.0582
• Mol File: 630067-21-9.mol

Chemical Properties

• Boiling Point: 384.9±37.0 °C(Predicted)
• Appearance: /
• Density: 1.579±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 2.98±0.38(Predicted)
• CAS DataBase Reference: 4,7-dichloroquinoline-3-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4,7-dichloroquinoline-3-carboxylic acid(630067-21-9)
• EPA Substance Registry System: 4,7-dichloroquinoline-3-carboxylic acid(630067-21-9)

Safety Data

• Hazardous Substances Data: 630067-21-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4,7-dichloroquinoline-3-carboxylic acid is used as an intermediate in the synthesis of various pharmaceuticals for its antimicrobial and antiparasitic properties. It aids in the development of new drugs to treat infections and diseases.
Used in Agrochemical Industry:
4,7-dichloroquinoline-3-carboxylic acid is used as a building block in the synthesis of agrochemicals to develop new pesticides and herbicides with enhanced efficacy.
Used in Material Science:
4,7-dichloroquinoline-3-carboxylic acid is used in the development of new materials due to its unique molecular structure and reactivity, contributing to advancements in various fields.
Used in Organic Synthesis:
4,7-dichloroquinoline-3-carboxylic acid is used as a valuable tool in organic synthesis for the creation of new compounds and products across different industries.

Upstream product

• 19499-19-5 4,7-dichloroquinoline-3-carboxylic acid ethyl ester 
• 86-98-6 4,7-dichloroquinoline 
• 124-38-9 carbon dioxide 

Relevant articles and documents

Base-Controlled Regioselective Functionalization of Chloro-Substituted Quinolines

We prepared a number of di- and trifunctionalized quinolines by selective metalation of chloro-substituted quinolines with metal amides followed by reaction with different electrophiles. Metalation of the C-3 position of the quinolinic ring with lithium diisopropylamide at -70 °C is easy to achieve, whereas reaction with lithium-magnesium and lithium-zinc amides affords C-2 or C-8 functionalized derivatives in a regioselective fashion. These complementary methods could be rationalized by DFT calculations and are convenient strategies toward the synthesis of bioactive quinoline derivatives such as chloroquine analogues.

5 -CYANO-4, 6 -DIAMINOPYRIMIDINE OR 6 -AMINOPURINE DERIVATIVES AS PI3K- DELTA INHIBITORS

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention aLso enables methods for treating cancers that are mediated, dependent on or associated with pi 105 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo- dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia ( T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.